Literature DB >> 15502899

[Bone marrow transplantation. Indications, chances and perspectives].

B Hertenstein1, A Ganser.   

Abstract

The hematopoietic stem cell transplantation has become an essential part of the treatment regimens in patients with acute and chronic leukemias, myelodysplastic syndromes, malignant lymphomas, multiple myeloma, and aplastic anemia. The decision to transplant depends on the stage of the disease, presence of risk factors, and age of the patient and should be taken by experienced hematologists/oncologists. Advances in immunogenetics have improved the treatment results of unrelated marrow donor transplantations. Better supportive care, modified conditioning regimens, and special graft preparations allow an allogeneic transplantation up to an age of 60 to 65 years, an autologous transplantation at an even higher age.

Entities:  

Mesh:

Year:  2004        PMID: 15502899     DOI: 10.1007/s00108-004-1287-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  20 in total

Review 1.  Second German consensus on immunogenetic donor search for allotransplantation of hematopoietic stem cells.

Authors:  H D Ottinger; C R Müller; S F Goldmann; E Albert; R Arnold; D W Beelen; R Blasczyk; D Bunjes; J Casper; W Ebell; G Ehninger; T Eiermann; H Einsele; A Fauser; S Ferencik; J Finke; B Hertenstein; A Heyll; T Klingebiel; A Knipper; B Kremens; H J Kolb; K Kolbe; E Lenartz; M Lindemann; C A Müller; J Mytilineos; D Niederwieser; V Runde; H Sayer; U W Schaefer; N Schmitz; S Schröder; R Schulze-Rath; R Schwerdtfeger; W Siegert; B Thiele; A R Zander; H Grosse-Wilde
Journal:  Ann Hematol       Date:  2001-10-25       Impact factor: 3.673

2.  Reduced-intensity conditioning or nonmyeloablative stem cell transplantation: introduction, rationale, and historic background.

Authors:  Shimon Slavin
Journal:  Semin Oncol       Date:  2004-02       Impact factor: 4.929

3.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

Authors:  T Philip; C Guglielmi; A Hagenbeek; R Somers; H Van der Lelie; D Bron; P Sonneveld; C Gisselbrecht; J Y Cahn; J L Harousseau
Journal:  N Engl J Med       Date:  1995-12-07       Impact factor: 91.245

4.  Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission.

Authors:  Michael G Kiehl; Ludwig Kraut; Rainer Schwerdtfeger; Bernd Hertenstein; Mats Remberger; Nicolaus Kroeger; Mathias Stelljes; Martin Bornhaeuser; Hans Martin; Christoph Scheid; Arnold Ganser; Axel R Zander; Joachim Kienast; Gerhard Ehninger; Dieter Hoelzer; Volker Diehl; Axel A Fauser; Olle Ringden
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

5.  Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma.

Authors:  Nicolaus Kröger; Rainer Schwerdtfeger; Michael Kiehl; Herbert Gottfried Sayer; Helmut Renges; Tatjana Zabelina; Boris Fehse; Florian Tögel; Georg Wittkowsky; Rolf Kuse; Axel Rolf Zander
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

6.  Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia.

Authors:  Norbert Schmitz; Meral Beksac; Dirk Hasenclever; Andrea Bacigalupo; Tapani Ruutu; Arnon Nagler; Eliane Gluckman; Nigel Russell; Jane F Apperley; Norbert C Gorin; Jeff Szer; Ken Bradstock; Agnes Buzyn; Peter Clark; Keith Borkett; Alois Gratwohl
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

7.  Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants.

Authors:  Georg Rauser; Hermann Einsele; Christian Sinzger; Dorothee Wernet; Gabriele Kuntz; Mario Assenmacher; John D M Campbell; Max S Topp
Journal:  Blood       Date:  2003-12-11       Impact factor: 22.113

8.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.

Authors:  H J Kolb; A Schattenberg; J M Goldman; B Hertenstein; N Jacobsen; W Arcese; P Ljungman; A Ferrant; L Verdonck; D Niederwieser; F van Rhee; J Mittermueller; T de Witte; E Holler; H Ansari
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

9.  A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.

Authors:  Corey S Cutler; Stephanie J Lee; Peter Greenberg; H Joachim Deeg; Waleska S Pérez; Claudio Anasetti; Brian J Bolwell; Mitchell S Cairo; Robert Peter Gale; John P Klein; Hillard M Lazarus; Jane L Liesveld; Philip L McCarthy; Gustavo A Milone; J Douglas Rizzo; Kirk R Schultz; Michael E Trigg; Armand Keating; Daniel J Weisdorf; Joseph H Antin; Mary M Horowitz
Journal:  Blood       Date:  2004-03-23       Impact factor: 22.113

10.  Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation.

Authors:  Sarah Marktel; Zulma Magnani; Fabio Ciceri; Sabrina Cazzaniga; Stanley R Riddell; Catia Traversari; Claudio Bordignon; Chiara Bonini
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.